Evidence map›Paper›PMID 34463331›Full record

ArticleEuropean heart journal. Cardiovascular pharmacotherapy2022

Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.

Emma F Magavern, Juan Carlos Kaski, Richard M Turner, Heinz Drexel, Azara Janmohamed, Andrew Scourfield, Daniel Burrage, Christopher N Floyd, Elizabeth Adeyeye, Juan Tamargo and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Cardiovascular pharmacotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Pharmacogenetics: Opportunities for theAnnual review of pharmacology and toxicology · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Emma F MagavernWilliam Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0003-0699-6411
Juan Carlos KaskiMolecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
Richard M TurnerThe Wolfson Centre for Personalised Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, UK.
Heinz DrexelVorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Feldkirch,Austria.
Azara JanmohamedDepartment of Clinical Pharmacology, St George's University of London, London, UK.
Andrew ScourfieldDepartment of Clinical Pharmacology, University College London Hospital Foundation Trust, London, UK.
Daniel BurrageWhittington Health NHS Trust, London, UK.
Christopher N FloydKing's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, UK.
Elizabeth AdeyeyeDepartment of Clinical Pharmacology, Cardiovascular Medicine, Barts Health NHS Trust, London, UK.
Juan TamargoDepartment of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Basil S LewisCardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Keld Per KjeldsenDepartment of Cardiology, Copenhagen University Hospital (Amager-Hvidovre), Copenhagen, Denmark.
Alexander NiessnerDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Sven WassmannCardiology Pasing, Munich,Germany.
Patrick SulzgruberDivision of Cardiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria.
Pascal BorryCenter for Biomedical Ethics and Law, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Stefan AgewallOslo University Hospital Ullevål and Institute of Clinical Sciences, University of Oslo, Oslo, Norway.
Anne Grete SembPreventive Cardio-Rheuma Clinic, Department of Rheumatology, Innovation and Research, Diakonhjemmet Hospital, Oslo, Norway.
Gianluigi SavareseDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm,Sweden.
Munir PirmohamedThe Wolfson Centre for Personalised Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, UK.
Mark J CaulfieldWilliam Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Funding

Department of HealthMedical Research Council G9521010Medical Research Council MR/L006758/1
6 · The paper itself

Abstract

Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.

Indexed as

CardiologyCardiovascular SystemEuropeHumansPharmacogeneticsGeneticsPharmacogenomicsPharmacotherapyTherapeutics

Identifiers

PMID34463331
PMCPMC12375864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.